Home › Prostate Cancer › NCT07141121

Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen

Who can join

Ages 18 and older · Men

Inclusion criteria:

* Localized or locally advanced prostate cancer D'Amico intermediate or high-risk disease.
* Indicated for robot-assisted radical prostatectomy
* Treatment naive.
* Age ≥ 18 years.
* Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria:

* Patients who have received pelvic radiation previously for prostate cancer or any other malignancy.
* Patients who have previously received androgen deprivation or other hormonal treatments, or focal therapy of prostate cancer prior to radical prostatectomy.
* Patients with D'Amico Criteria low risk prostate cancer.

About the study

This study investigates a new, faster way to find cancer cells on the surface of the prostate during radical prostatectomy surgery. A recently FDA-approved device, called the Histolog Scanner, gives high-resolution imaging of the surface of fresh tissue using ultra-fast confocal microscopy, which allows physicians to make surgical decisions quickly.

What is being tested

• Histolog Scan (device)

Sponsor: Icahn School of Medicine at Mount Sinai · Participants: 78 · Started: May 13, 2025

Contact the study team

• Monali Fatterpekar, PhD · Phone: (347) 675-8024
• Henry W. Jodka, BA · Phone: 203-939-5115

Official record on ClinicalTrials.gov — NCT07141121

Locations in the U.S.

Conditions

• Prostate Cancer
• Margins of Excision

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.